Previous New Releases from NCBI BookshelfBelantamab mafodotin (Blenrep), bortezomib, dexamethasone: Indication: Belantamab mafodotin is indicated in combination with bortezomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy: Reimbursement Recommendation [Internet].Belantamab mafodotin (Blenrep), bortezomib, dexamethasone: Indication: Belantamab mafodotin is indicated in combination with bortezomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy: Reimbursement Recommendation [Internet].
